A Phase 1 interventional study of Lenvatinib in Solid Tumor or Lymphoma, sponsored by Eisai Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Eisai Inc. · Phase 1, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Lymphoma with a site in Netherlands — 8 open to participants now, 19 under way, 8 of them phase 3. Lymphoma · Netherlands.
Among the 72 studies in Lymphoma with a site in Netherlands, this one is the 42nd largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2005, is one of 10 in phase 1, and was the 23rd registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →8 of the 72 studies in Lymphoma with a site in Netherlands are open now. Recruiting first, the newest first:
SecuraBio · Sites in Netherlands, Belgium, Czechia and 7 more countries
Ages 18+
Academisch Ziekenhuis Maastricht · Sites in Netherlands
Ages 18+
Nurix Therapeutics, Inc. · Sites in Netherlands, United States, France and 5 more countries
Ages 18+
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Sites in Netherlands, Denmark, France and 3 more countries
Ages 18–99
Rotkreuzklinikum München gGmbH · Sites in Netherlands, Germany, Spain and 1 more country
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 27 · Phase 3 29
First in 1989; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 119 across the 67 interventional studies, 105 across the 4 observational. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 72 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 7 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
6 of the studies in Lymphoma with a site in Netherlands that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06356129Phase 3CelgeneStudy to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma | 2027-08-09 |
| NCT04662255Phase 3Loxo Oncology, Inc.Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) | 2027-11 |
| NCT05131022Nurix Therapeutics, Inc.A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | 2027-01 |
| NCT05223413Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIREmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs | 2027-06 |
| NCT04986293University Medical Center GroningenCPAP or BiPAP for Motion Mitigation During Radiotherapy | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 72 studies in Lymphoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the maximum tolerated dose (MTD) of lenvatinib in patients with solid tumors or lymphomas.
This is an open-label, non-randomized, dose escalation study. Patients will be treated with lenvatinib once daily. Each four-week treatment period will be considered to be one treatment cycle. The selection of subsequent dose levels will be performed according to an accelerated design: Although initially 3 patients per dose level will be entered, the next dose level can be opened for patient accrual after only the first patient in the previous cohort completes Cycle 1 with no drug-related toxicity greater than grade 1 (except alopecia, lymphopenia and anemia).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the inclusion criteria outlined below in order to be eligible to participate in the study:
EXCLUSION CRITERIA:
Patients with the following characteristics will not be eligible for the study:
Any of the following laboratory parameters:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lenvatinib
Lenvatinib tablets taken orally, once daily.
Also known as: E7080
Maximum Tolerated Dose (MTD)
The MTD was defined as the highest dose level at which no more than one out of six participants experienced dose-limiting toxicity (DLT). DLT was assessed during the first 4 weeks of therapy (Cycle 1) for dose escalation purposes. Participants enrolled into the MTD cohort were given the option to also participate in the food-effect pilot study. The food-effect pilot study was initiated once the MTD had been established.
Time frame: Cycle 1 (4 weeks)
Summary of Adverse Events (AEs) and Serious Adverse Events (SAEs)
All AEs were graded on a 5-point scale according to the National Cancer Institute's Common Toxicity Criteria (NCI CTC) grading system, version 3.0. Safety was assessed using the occurrence of DLTs, AEs, SAEs, clinical laboratory test results, vital signs measurements, physical examination findings, and electrocardiograms (ECGs) readings. An AE was defined as any untoward medical occurrence in a participant administered lenvatinib and did not necessarily have a causal relationship to lenvatinib. An SAE was defined as any untoward medical occurrence which results in death, was life-threatening, required hospitalization or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect. Treatment-related AEs and SAEs are AEs considered probably or possibly related to lenvatinib.
Time frame: First date of study treatment to date of last dose of study treatment, up to approximately 13 years and 8 months
Dose-limiting Toxicities (DLTs)
A DLT was defined as any grade 3 or higher hematological or non-hematological toxicity directly related to lenvatinib, any repeated National Cancer Institute Common Toxicity Criteria (NCI CTC) grade 2 hematological or non-hematological toxicity considered to be directly related to lenvatinib and required dose reduction, or failure to administer greater than or equal to 75% of the planned dosage of lenvatinib during Cycle 1 as a result of treatment-related failure.
Time frame: Cycle 1 (4 weeks) of each dose level
Treatment-Related Adverse Events (All Grades) With an Overall Incidence Greater Than or Equal to 10%
Treatment-related AEs were untoward medical events that were considered by the investigator to be possibly or probably related to lenvatinib.
Time frame: First date of study treatment to date of withdrawal from study or last dose of study treatment, up to approximately 13 years and 8 months
Best Overall Response (BOR)
BOR was the best confirmed response of complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD), or not evaluable (NE), recorded from the start of lenvatinib until disease progression/recurrence or death. CR; disappearance of all target lesions for at least 1 month. PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD; a 20% or greater increase in the sum of the longest diameter of measured lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions. SD; PR failed to be achieved in the overall response assessment and there was no PD observed at 7 weeks or later after starting lenvatinib.
Time frame: Baseline to first date of documented CR, PR, SD, or PD, assessed up to approximately 4 years
Maximum Plasma Concentration (Cmax) of Lenvatinib
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Time to Maximum Plasma Concentration (Tmax) of Lenvatinib
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Apparent Plasma Half-life (t1/2) of Lenvatinib
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Area Under the Plasma Concentration Curve From Time 0 to Infinity (AUC(0-inf))
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Area Under the Plasma Concentration Curve From Time 0 to 24 Hours (AUC(0-24))
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Clearance Corrected for the Fraction of Lenvatinib Absorbed (CL/F)
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Apparent Volume of Distribution (Vz/F)
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Fraction of Unchanged Lenvatinib Excreted in the Urine (fe)
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Renal Clearance (CLr) of Lenvatinib
Time frame: Cycles 1 and 2 Day 1: 0-24 hours postdose (Cycle length = 28 days)
Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24))
Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib
Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib
Time frame: Cycle 1 Day 15 and Day 22: 0-24 hours postdose (Cycle length = 28 days)
Pharmacodynamic (PD) Biomarkers of Lenvatinib in Peripheral Blood Mononuclear Cells (PBMCs) and Tumor Samples
Based on the data in assay development stage before PD biomarker analysis in study E7080-E044-101 we did not find the appropriate PD biomarker in PBMC, therefore we did not have any biomarker analysis for PK/PD analysis.
Time frame: Blood: Cycle 1 Day 1, Day 15, or Day 22, Cycle 2 Day 1 Tumor tissue: Screening and after at least one 28-day Cycle of study treatment
Participants took part in the study at 1 site in United Kingdom and 1 site in Netherlands from 01 July 2005 to 01 March 2019.
| Milestone | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib Fasted/Fed 25 mg | Lenvatinib Fed/Fasted 25 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 4 | 4 | 4 | 3 | 3 | 3 | 12 | 9 | 6 | 3 | 0 | 0 | 24 | 7 |
| Completed | 4 | 4 | 4 | 3 | 3 | 3 | 12 | 9 | 6 | 3 | 0 | 0 | 24 | 7 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib Fasted/Fed 25 mg | Lenvatinib Fed/Fasted 25 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The MTD was defined as the highest dose level at which no more than one out of six participants experienced dose-limiting toxicity (DLT). DLT was assessed during the first 4 weeks of therapy (Cycle 1) for dose escalation purposes. Participants enrolled into the MTD cohort were given the option to also participate in the food-effect pilot study. The food-effect pilot study was initiated once the MTD had been established.
| milligram (mg) | Lenvatinib |
|---|---|
| Maximum Tolerated Dose (MTD) | 25 |
All AEs were graded on a 5-point scale according to the National Cancer Institute's Common Toxicity Criteria (NCI CTC) grading system, version 3.0. Safety was assessed using the occurrence of DLTs, AEs, SAEs, clinical laboratory test results, vital signs measurements, physical examination findings, and electrocardiograms (ECGs) readings. An AE was defined as any untoward medical occurrence in a participant administered lenvatinib and did not necessarily have a causal relationship to lenvatinib. An SAE was defined as any untoward medical occurrence which results in death, was life-threatening, required hospitalization or prolonged hospitalization, resulted in persistent or significant disability/incapacity, or caused a congenital anomaly/birth defect. Treatment-related AEs and SAEs are AEs considered probably or possibly related to lenvatinib.
| Percentage of participants | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib Fasted/Fed 25 mg | Lenvatinib Fed/Fasted 25 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse events | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |
| Treatment-related adverse events | 75.0 | 75.0 | 50.0 | 66.7 | 100.0 | 100.0 | 91.7 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 85.7 |
| Serious adverse events | 50.0 | 50.0 | 25.0 | 33.3 | 0 | 100.0 | 41.7 | 44.4 | 33.3 | 100.0 | 33.3 | 40.0 | 62.5 | 42.9 |
| Treatment-related serious adverse events | 25.0 | 0 | 25.0 | 0 | 0 | 33.3 | 8.3 | 11.1 | 33.3 | 66.7 | 16.7 | 20.0 | 33.3 | 14.3 |
A DLT was defined as any grade 3 or higher hematological or non-hematological toxicity directly related to lenvatinib, any repeated National Cancer Institute Common Toxicity Criteria (NCI CTC) grade 2 hematological or non-hematological toxicity considered to be directly related to lenvatinib and required dose reduction, or failure to administer greater than or equal to 75% of the planned dosage of lenvatinib during Cycle 1 as a result of treatment-related failure.
| Participants | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Febrile neutropenia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Proteinuria | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Thrombocytopenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Hypertension | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Fatigue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Treatment-related AEs were untoward medical events that were considered by the investigator to be possibly or probably related to lenvatinib.
| Percentage of participants | Lenvatinib 0.2 - 6.4 mg | Lenvatinib 12 - 20 mg | Lenvatinib 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|
| Hypertension | 10 | 40 | 63 | 57 |
| Nausea | 38 | 17 | 58 | 43 |
| Diarrhoea | 19 | 27 | 50 | 57 |
| Stomatitis | 5 | 20 | 63 | 57 |
| Proteinuria | 14 | 27 | 29 | 43 |
| Vomiting | 33 | 10 | 33 | 14 |
| Lethargy | 14 | 17 | 38 | 29 |
| Dysphonia | 0 | 13 | 46 | 43 |
| Dry skin | 5 | 10 | 46 | 14 |
| Fatigue | 10 | 23 | 21 | 14 |
| Anorexia | 10 | 17 | 21 | 29 |
| Constipation | 10 | 10 | 33 | 14 |
| Headache | 0 | 7 | 29 | 29 |
| Abdominal pain | 0 | 7 | 29 | 0 |
BOR was the best confirmed response of complete response (CR), partial response (PR), progressive disease (PD), stable disease (SD), or not evaluable (NE), recorded from the start of lenvatinib until disease progression/recurrence or death. CR; disappearance of all target lesions for at least 1 month. PR; at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD; a 20% or greater increase in the sum of the longest diameter of measured lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of one or more new lesions. SD; PR failed to be achieved in the overall response assessment and there was no PD observed at 7 weeks or later after starting lenvatinib.
| Percentage of participants | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Partial response | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 0 | 33.3 | 12.5 | 28.6 |
| Stable disease | 0 | 0 | 25.0 | 33.3 | 66.7 | 0 | 33.3 | 55.6 | 83.3 | 33.3 | 66.7 | 42.9 |
| Progressive disease | 50.0 | 50.0 | 0 | 0 | 0 | 33.3 | 41.7 | 11.1 | 16.7 | 0 | 8.3 | 0 |
| Not evaluable | 25.0 | 0 | 0 | 0 | 0 | 0 | 8.3 | 0 | 0 | 0 | 0 | 0 |
| Nanogram per milliliter (ng/mL) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.753 ± 0.2176 | 1.740 ± 0.6921 | 4.255 ± 1.7474 | 20.967 ± 11.6741 | 49.883 ± 15.9952 | 127.067 ± 91.3320 | 259.990 ± 108.1789 | 209.004 ± 112.0090 | 375.077 ± 158.1811 | 408.797 ± 105.6923 | 630.589 ± 234.1659 | 649.927 ± 237.7462 |
| Cycle 2 Day 1 | 2.385 ± 0.5162 | 5.477 ± 1.5988 | 9.610 ± 2.3193 | 36.483 ± 10.9339 | 92.137 ± 29.0365 | 197.217 ± 136.7307 | 291.414 ± 146.1972 | 187.467 ± 86.3962 | 368.937 ± 148.8160 | 238.670 ± NA | 544.718 ± 183.1259 | 562.416 ± 121.4056 |
| Hours | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 4.280 ± 1.440 | 5.785 ± 2.569 | 3.263 ± 1.194 | 3.973 ± 3.494 | 9.557 ± 12.658 | 2.023 ± 1.035 | 2.348 ± 1.144 | 1.897 ± 0.7768 | 2.287 ± 0.3881 | 2.533 ± 0.826 | 1.770 ± 0.715 | 2.674 ± 2.038 |
| Cycle 2 Day 1 | 2.225 ± 0.3889 | 2.680 ± 0.589 | 13.475 ± 14.814 | 2.360 ± 1.179 | 2.173 ± 0.583 | 2.103 ± 0.405 | 2.021 ± 1.295 | 1.944 ± 0.604 | 2.352 ± 0.705 | 3.000 ± NA | 2.983 ± 1.481 | 1.500 ± 0.408 |
| Hours | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 18.180 ± 11.342 | 10.695 ± 8.789 | 12.805 ± 3.118 | 8.077 ± 0.749 | 5.981 ± 0.4840 | 6.567 ± 0.9553 | 7.115 ± 1.0866 | 6.960 ± 1.230 | 5.848 ± 1.018 | 5.550 ± 0.599 |
| Cycle 2 Day 1 | 29.540 ± 8.2731 | 26.380 ± 8.0427 | 20.840 ± NA | 10.827 ± 5.555 | 9.973 ± 1.288 | 8.330 ± 0.517 | 6.935 ± 1.1681 | 6.829 ± 1.019 | 6.935 ± 0.9313 | 8.090 ± NA | 6.025 ± 0.704 | 6.675 ± 0.5216 |
| nanogram*hour per milliliter (ng*hr/mL) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 123.745 ± 20.810 | 376.645 ± 312.1240 | 780.275 ± 189.116 | 1335.493 ± 894.562 | 1895.454 ± 467.145 | 1693.298 ± 1011.7941 | 3683.590 ± 2210.4521 | 4238.680 ± 2602.9271 | 4413.263 ± 1946.571 | 4383.678 ± 1697.248 |
| Cycle 2 Day 1 | 99.325 ± 0.1202 | 174.310 ± 46.259 | 370.390 ± NA | 585.247 ± 397.909 | 1150.393 ± 192.365 | 1952.430 ± 1323.783 | 2278.016 ± 851.258 | 1558.101 ± 760.687 | 3310.673 ± 1544.708 | 2260.040 ± NA | 4549.825 ± 1161.045 | 4391.160 ± 997.486 |
| ng*hr/mL | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 14.348 ± 4.500 | 30.207 ± 14.521 | 61.915 ± 17.164 | 220.910 ± 129.838 | 659.553 ± 209.129 | 1168.257 ± 799.169 | 1655.035 ± 555.479 | 1537.476 ± 876.6805 | 3250.843 ± 1826.8789 | 3709.550 ± 2059.6379 | 4074.803 ± 1666.2780 | 4601.014 ± 1887.3642 |
| Cycle 2 Day 1 | 43.305 ± 8.5913 | 85.477 ± 37.054 | 199.100 ± NA | 422.873 ± 270.528 | 931.307 ± 179.514 | 1691.160 ± 1167.750 | 2052.965 ± 789.504 | 1422.584 ± 697.699 | 2947.920 ± 1286.805 | 1934.500 ± NA | 4224.095 ± 1120.837 | 4020.185 ± 899.182 |
| Liter per hour (L/hr) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 6.560 ± 1.103 | 6.470 ± 5.360 | 4.225 ± 1.0253 | 8.190 ± 7.923 | 6.614 ± 1.336 | 9.534 ± 4.307 | 6.157 ± 4.240 | 5.980 ± 3.236 | 6.863 ± 3.354 | 8.827 ± 5.058 |
| Cycle 2 Day 1 | 4.710 ± 0.9334 | 5.200 ± 1.802 | 4.020 ± NA | 5.347 ± 3.942 | 3.533 ± 0.747 | 5.557 ± 4.200 | 6.896 ± 3.360 | 10.110 ± 3.321 | 6.437 ± 3.668 | 10.340 ± NA | 6.378 ± 2.302 | 7.978 ± 2.763 |
| Liter (L) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | — | — | 162.975 ± 78.383 | 65.795 ± 0.6435 | 80.365 ± 37.922 | 97.190 ± 95.442 | 57.039 ± 11.887 | 88.069 ± 38.174 | 58.408 ± 32.346 | 56.350 ± 22.932 | 55.263 ± 22.411 | 68.073 ± 32.456 |
| Cycle 2 Day 1 | 206.360 ± 96.068 | 208.937 ± 114.969 | 120.810 ± NA | 65.437 ± 24.894 | 51.487 ± 16.805 | 67.747 ± 51.897 | 70.881 ± 40.419 | 99.960 ± 37.787 | 60.683 ± 26.763 | 120.730 ± NA | 57.143 ± 28.550 | 76.610 ± 25.967 |
| Percentage of lenvatinib | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.530 ± 0.0141 | 0.253 ± 0.0457 | 0.217 ± 0.0896 | 0.363 ± 0.1290 | 0.355 ± 0.0354 | 0.390 ± 0.0849 | 0.487 ± 0.3137 | 0.783 ± 0.7928 | 0.348 ± 0.1910 | 0.690 ± 0.4851 | 0.576 ± 0.3042 | 0.503 ± 0.3004 |
| Cycle 2 Day 1 | 1.240 ± NA | 0.715 ± 0.1626 | 0.605 ± 0.0636 | 0.535 ± 0.3748 | 1.050 ± NA | 0.557 ± 0.2212 | 0.689 ± 0.4208 | 0.663 ± 0.2873 | 0.825 ± 0.2786 | 0.630 ± NA | 0.778 ± 0.3801 | 0.527 ± 0.1595 |
| L/hour | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | 0.060 ± 0.0064 | 0.037 ± 0.0167 | 0.027 ± 0.0042 | 0.035 ± 0.0233 | 0.021 ± 0.0113 | 0.017 ± 0.0078 | 0.039 ± 0.0243 | 0.064 ± 0.0534 | 0.020 ± 0.0095 | 0.046 ± 0.0466 | 0.041 ± 0.0233 | 0.035 ± 0.0144 |
| Cycle 2 Day 1 | 0.050 ± NA | 0.045 ± 0.011 | 0.022 ± NA | 0.029 ± 0.0042 | 0.034 ± NA | 0.025 ± 0.0097 | 0.050 ± 0.0304 | 0.069 ± 0.021 | 0.048 ± 0.36 | 0.065 ± NA | 0.52 ± 0.019 | 0.045 ± 0.0247 |
| ng*hr/mL | Lenvatinib Fed 25 mg | Lenvatinib Fasted 25 mg |
|---|---|---|
| Effect of Food on the Area Under the Curve From Zero to 24 Hours (AUC(0-24)) | 3851.773 ± 993.1449 | 4039.681 ± 1567.4169 |
| ng/mL | Lenvatinib Fed 25 mg | Lenvatinib Fasted 25 mg |
|---|---|---|
| Effect of Food on the Maximum Plasma Concentration (Cmax) of Lenvatinib | 508.558 ± 165.7591 | 544.058 ± 248.5409 |
| Hours | Lenvatinib Fed State 25 mg | Lenvatinib Fasted State 25 mg |
|---|---|---|
| Effect of Food on Time to Maximum Concentration (Tmax) of Lenvatinib | 4.980 (2.00 to 5.07) | 2.030 (1.00 to 3.07) |
Based on the data in assay development stage before PD biomarker analysis in study E7080-E044-101 we did not find the appropriate PD biomarker in PBMC, therefore we did not have any biomarker analysis for PK/PD analysis.
No measurements were reported for this outcome.
Collected over All adverse events (AEs) were collected for up to approximately 13 years and 8 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenvatinib 0.2 mg | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Lenvatinib 0.4 mg | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Lenvatinib 0.8 mg | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Lenvatinib 1.6 mg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Lenvatinib 3.2 mg | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Lenvatinib 6.4 mg | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Lenvatinib 12 mg | 1/12 (8.3%) | 5/12 (41.7%) | 12/12 (100%) |
| Lenvatinib 12.5 mg | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Lenvatinib 16 mg | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Lenvatinib 20 mg | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Lenvatinib Fasted/Fed 25 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Lenvatinib Fed/Fasted 25 mg | 0/5 (0%) | 2/5 (40%) | 5/5 (100%) |
| Lenvatinib (MTD Cohort) 25 mg | 3/24 (12.5%) | 15/24 (62.5%) | 24/24 (100%) |
| Lenvatinib 32 mg | 2/7 (28.6%) | 3/7 (42.9%) | 6/7 (85.7%) |
| Event | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib Fasted/Fed 25 mg | Lenvatinib Fed/Fasted 25 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 1/3 | 1/12 | 0/9 | 0/6 | 0/3 | 0/6 | 0/5 | 3/24 | 0/7 |
| VomitingGastrointestinal disorders | 0/4 | 1/4 | 0/4 | 0/3 | 0/3 | 1/3 | 0/12 | 0/9 | 0/6 | 0/3 | 0/6 | 0/5 | 3/24 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 1/24 | 0/7 |
| HaematemesisGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 0/7 |
| MelaenaGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 0/7 |
| PyrexiaGeneral disorders | 0/4 | 1/4 | 0/4 | 0/3 | 0/3 | 1/3 | 0/12 | 1/9 | 0/6 | 0/3 | 0/6 | 1/5 | 1/24 | 0/7 |
| General physical health deteriorationGeneral disorders | 0/4 | 0/4 | 0/4 | 1/3 | 0/3 | 1/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 0/7 |
| MalaiseGeneral disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 0/7 |
| Lower respiratory tract infectionInfections and infestations | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 1/7 |
| InfectionInfections and infestations | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 0/12 | 0/9 | 0/6 | 1/3 | 0/6 | 0/5 | 0/24 | 0/7 |
| Event | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib Fasted/Fed 25 mg | Lenvatinib Fed/Fasted 25 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/4 | 3/4 | 2/4 | 2/3 | 3/3 | 2/3 | 3/12 | 2/9 | 2/6 | 3/3 | 4/6 | 5/5 | 17/24 | 3/7 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 2/4 | 1/4 | 1/3 | 2/3 | 0/3 | 3/12 | 3/9 | 3/6 | 3/3 | 5/6 | 4/5 | 16/24 | 4/7 |
| VomitingGastrointestinal disorders | 1/4 | 2/4 | 1/4 | 1/3 | 3/3 | 0/3 | 4/12 | 4/9 | 1/6 | 2/3 | 1/6 | 4/5 | 13/24 | 1/7 |
| StomatitisGastrointestinal disorders | 0/4 | 1/4 | 0/4 | 0/3 | 1/3 | 1/3 | 3/12 | 2/9 | 3/6 | 1/3 | 5/6 | 3/5 | 15/24 | 4/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/4 | 1/4 | 3/4 | 1/3 | 0/3 | 0/3 | 0/12 | 3/9 | 1/6 | 1/3 | 1/6 | 1/5 | 5/24 | 3/7 |
| DyspepsiaGastrointestinal disorders | 1/4 | 0/4 | 0/4 | 0/3 | 0/3 | 0/3 | 1/12 | 0/9 | 0/6 | 2/3 | 1/6 | 1/5 | 4/24 | 0/7 |
| ToothacheGastrointestinal disorders | 0/4 | 0/4 | 0/4 | 0/3 | 0/3 | 2/3 | 0/12 | 2/9 | 0/6 | 0/3 | 1/6 | 0/5 | 1/24 | 0/7 |
| LethargyNervous system disorders | 1/4 | 1/4 | 0/4 | 1/3 | 2/3 | 1/3 | 3/12 | 3/9 | 1/6 | 0/3 | 1/6 | 0/5 | 10/24 | 2/7 |
| FatigueGeneral disorders | 1/4 | 0/4 | 0/4 | 1/3 | 0/3 | 1/3 | 3/12 | 3/9 | 2/6 | 1/3 | 4/6 | 2/5 | 8/24 | 3/7 |
| PyrexiaGeneral disorders | 0/4 | 1/4 | 0/4 | 1/3 | 2/3 | 0/3 | 1/12 | 0/9 | 0/6 | 2/3 | 2/6 | 3/5 | 7/24 | 1/7 |
Intent-to-treat (ITT) population included all participants who received at least one dose of lenvatinib.
| Age, Continuous(Years) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 64.5 ± 7.94 | 47.8 ± 6.45 | 64.0 ± 6.48 | 60.0 ± 11.53 | 65.0 ± 19.00 | 51.0 ± 22.72 | 46.3 ± 13.25 | 52.6 ± 13.28 | 55.7 ± 13.32 | 51.7 ± 12.34 | 52.2 ± 9.65 | 53.9 ± 11.84 | 53.4 ± 12.32 |
| Sex: Female, Male(Participants) | Lenvatinib 0.2 mg | Lenvatinib 0.4 mg | Lenvatinib 0.8 mg | Lenvatinib 1.6 mg | Lenvatinib 3.2 mg | Lenvatinib 6.4 mg | Lenvatinib 12 mg | Lenvatinib 12.5 mg | Lenvatinib 16 mg | Lenvatinib 20 mg | Lenvatinib (MTD Cohort) 25 mg | Lenvatinib 32 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 1 | 2 | 0 | 8 | 3 | 3 | 0 | 14 | 1 | 39 |
| Male | 2 | 1 | 2 | 2 | 1 | 3 | 4 | 6 | 3 | 3 | 10 | 6 | 43 |
Ran from Jul 2005 to primary completion in Jun 2009, 47 months.
Results were first posted in May 2016, 6 years 11 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 47 months is close to that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenvatinib